There are currently 1844 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Enhancing PAP Adherence Among Spanish-speaking Hispanic Adults With OSA
NCT05618444
Recruiting
This study seeks to enhance long-term positive airway pressure (PAP) adherence among Spanish-speaking Hispanics, a group with known PAP outcomes disparities. This study will assess the feasibility of a linguistically and culturally adapted tele-management intervention (Automated Management, AM) for Spanish-speaking Hispanic adults with OSA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Obstructive Sleep Apnea
Register for Updates
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
NCT04252066
Recruiting
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/06/2024
Locations: Amicus Therapeutics, Inc. Pregnancy Registry, Philadelphia, Pennsylvania
Conditions: Fabry Disease
Register for Updates
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Register for Updates
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03190278
Recruiting
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2024
Locations: University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Register for Updates
LE as a Marker for Periprosthetic Joint Infection
NCT05440032
Recruiting
Testing and comparison of a novel point-of-care electrochemical assay to detect and help diagnose periprosthetic joint infection on the hip and knee to the standard of care test
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Rothman Orthopaedic Institute, Philadelphia, Pennsylvania
Conditions: Prosthetic-joint Infection
Register for Updates
A Study of AT-02 in Subjects With Systemic Amyloidosis.
NCT05951049
Recruiting
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/29/2024
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Amyloidosis; Systemic
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
mychoiceTM Implementation With Medical Oncology Patients
NCT06222242
Recruiting
This is a pragmatic, non-randomized mixed-methods evaluation study designed to evaluate the feasibility and acceptability of delivering the mychoiceTM tool to new Medical Oncology patients as well as to more deeply explore its value to patients in their discussion with their provider about clinical trials as a treatment option over the course of their oncology treatment (Effectiveness).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
Outcomes of Functional Substrate Mapping of Ventricular Tachycardia
NCT05708131
Recruiting
The goal of this registry database is to demonstrate the safety and effectiveness of functional ventricular tachycardia (VT) ablation using SENSE protocol in patients with ischaemic VT. Mortality and the need for ICD therapies at 12 months post-ablation will be compared with propensity-matched controls undergoing substrate-based ablation alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ventricular Tachycardia
Register for Updates
Randomized Trial of Intraoperative IV Versus Preoperative Oral Acetaminophen During Ambulatory Lumbar Discectomy
NCT04574778
Recruiting
Effective non-opioid analgesics are of particular interest in ambulatory surgery, as providers may be able to reduce pain while avoiding perioperative opioids that can delay same day discharge. The value of maintaining an efficient flow of patients from the perioperative area to discharge is an important metric for same day surgery centers, and an improvement in efficiency with IV acetaminophen could potentially offset the increased cost of the medication while providing a more pleasant surgical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: Rothman Orthopaedic Institute, Philadelphia, Pennsylvania
Conditions: Pain, Postoperative, Spine Surgery
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
ALL
Ages:
All
Trial Updated:
01/09/2024
Locations: Titleman Orthopedic, Philadelphia, Pennsylvania
Conditions: Pareses, Lower Extremity
Register for Updates
Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05627232
Recruiting
This phase I trial tests the safety, side effects, and best dose of palbociclib or tazemetostat in combination with CPX-351 in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or does not respond to treatment (refractory). CPX-351 is a combination of the chemotherapy drugs, daunorubicin and cytarabine, which is the standard of care for AML. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Register for Updates